Vaxgen bemüht sich gerade ,die Zulassung für den Impfstoff von Kaketsuken in USA zu bekommen BRISBANE, Calif., Dec. 19 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Nasdaq: VXGN, news) today announced the correction of statements reported in the news media, including Bloomberg Business News, The New York Times, Reuters, San Jose Mercury News and other publications that report or suggest VaxGen has commercial rights to market and sell in the U.S. an attenuated smallpox vaccine which VaxGen is developing with the Chemo-Sero-Therapeutic Research Institute ("Kaketsuken"). These statements are incorrect. As the company announced in its press release dated December 17, 2002, VaxGen has entered into an agreement to initiate clinical development and pursue regulatory approval from the FDA for the vaccine. VaxGen is currently negotiating the specific terms of commercial arrangements between VaxGen and Kaketsuken. Such an agreement for marketing and sale of the vaccine in the U.S. and internationally is dependent on successfully developing and receiving approval for sale by regulatory authorities. No definitive agreement with regard to the commercial terms, including exclusivity or territories, has been reached with Kaketsuken. Statements made by VaxGen to Bloomberg and in our conference call of December 17, 2002, with respect to commercial terms were statements of belief as to the expected outcome of VaxGen's negotiations based on discussions and proposals with Kaketsuken.
BRISBANE, Calif. and KUMAMOTO, Japan, Dec. 17 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Nasdaq: VXGN, news) and the Chemo-Sero-Therapeutic Research Institute (Kaketsuken) announced today that they have entered into initial agreements that will allow VaxGen to initiate development of Kaketsuken's attenuated smallpox vaccine for use in the United States. VaxGen believes that the vaccine, licensed in Japan in 1980, will have a better safety profile, yet be equally effective, compared to smallpox vaccines currently available in the United States. The vaccine, LC16-Kaketsuken, already has been administered to approximately 50,000 Japanese children, in whom no serious side effects were observed. " ... In a field trial of 50,000 persons, (the vaccine) was found to produce a markedly lower frequency of reactions than that noted for other strains" of vaccinia used to make smallpox vaccines, according to the authoritative reference, Vaccines.
ist offenbar deutlich weniger gefährlich als die bisherigen Impfstoffe
Vaxgen ist auch hochinteressant,weil sie einen Impfstoff gegen Aids entwickeln
Dec. 16, 2002 BRISBANE, Calif. (CBS.MW) -- Shares of VaxGen surged more than 20 percent Monday after federal regulators pledged to give a speedy review to the small biotech firm's experimental AIDS vaccines.The fast-track designation doesn't guarantee approval. VaxGen has long faced doubts about whether its vaccine can gain marketing clearance. Reflecting that skepticism, the company's stock is a favorite among short sellers, who profit if the share price declines.
On Friday, VaxGen's shares plunged after an article in Nature, one of the most prestigious science journals in the world, raised questions about whether the type of vaccine VaxGen is developing would be effective against HIV.
Developing an AIDS vaccine is considered enormously difficult because the virus is so quick to mutate.Of all the efforts to develop an AIDS vaccine, VaxGen's program is believed to be the furthest along, having reached late-stage patient testing.
|
Thread abonnieren
